S rq wThis study was performed to determine the changes in pulnonary function in patients randomised to receive treatment with four cycles of bleomycin, etoposide and cisplatin (BEP) The standard chemotherapy for patients with diinated tsticular germ cell tumours consists of a combination of bleomycin, etoposide and cisplatin (BEP) (Williams et al., 1987), lading to an overall 5 year survival of these patients of 87% (Dearnaley et al., 1991) . A major disadvantage of this treatment is the occurrnce of bleomycin-induced pneumonitis (BIP). The reported inc of this toxicity varies from 0 to 46% of the patients receiving a bleomycincontaining therapy (De Lena et al., 1972; Van Bameveld et al., 1984; Williams et al., 1987; Juls-Elysee et al., 1990; Dernaley et al., 1991; Osanto et al., 1992) . Fatal BIP occurs in approximately 3% of patients treated with bleomycin (Levi et al., 1993) . However, bleomycin nowadays is only used as part of a multidrug chemotherapeutic reilmen, and so the impact of bleomycin alone on lung function is not known.
S rq wThis study was performed to determine the changes in pulnonary function in patients randomised to receive treatment with four cycles of bleomycin, etoposide and cisplatin (BEP) (27 patients) or with four cyces of etoposide and cisplatin (EP) (27 patiets) for ssemnated non-semiomatous lar ncmer. Tlis enabled us to establish whether efects other than those due to bleomycin determined the detrimental effects of BEP on hmg function asssNNF ents. Slow inpiratory vital capacity (VC), the transfer factor of the hmgs for carbon monoxide (Tun), the diffusing capacity of the alveolo-capillary membrane (D.), the pulnonary capillary blood volume (Vj) and the tramnsfer factor of the hmgs for carbon monoxide per unit ahliar vohlme (Km) wr determined before and at 3 }wk intervals during chemotherapy. Both groups, similar in terms of factors that may influe pulmonary function, showed during therapy a sigfant decreas in To compared with the pretreatment vahlc. Only at the end of the therapy was a sificant diffen in T between both groups observed. Jdiminished also significantly in both groups during treatment, but differences between both groups wem not sen. VC and V, decreased in patiets reciving BEP but reMained constant during treatment with EP. It can be cocxed that the D., Kco, and the widely used TLCO are not suitable parameters to monitor speifically pulmonary toxicty induced by bleomycin as part of a mulidrug regimen. However, VC and V, appear to be proper lung function asseNssents which reflect spcifically alterations induced by bloomycin.
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The standard chemotherapy for patients with diinated tsticular germ cell tumours consists of a combination of bleomycin, etoposide and cisplatin (BEP) (Williams et al., 1987) , lading to an overall 5 year survival of these patients of 87% (Dearnaley et al., 1991) . A major disadvantage of this treatment is the occurrnce of bleomycin-induced pneumonitis (BIP). The reported inc of this toxicity varies from 0 to 46% of the patients receiving a bleomycincontaining therapy (De Lena et al., 1972; Van Bameveld et al., 1984; Williams et al., 1987; Juls-Elysee et al., 1990; Dernaley et al., 1991; Osanto et al., 1992) . Fatal BIP occurs in approximately 3% of patients treated with bleomycin (Levi et al., 1993) . However, bleomycin nowadays is only used as part of a multidrug chemotherapeutic reilmen, and so the impact of bleomycin alone on lung function is not known.
The transfer factor of the lungs for carbon monoxide (TLC) is assumed to reflect alterations in the lungs caused by bleomycin, and therefore TLCO has become a tool to detect BIP (Comis, 1992 (Luursema et al., 1983; Van Barneveld et al., 1985) . Moreover, we showed that when BIP occurs it is completely reversible with time (Van Barneveld et al., 1987 Cotes (1979) (Figure 1 ). This decline was signint in both groups in week 6 (P<0.01). This decline continued, and the difference from the pretreatment (Adamson et al., 1974) , it was assumed that the reduction in TLO observed during treatment of patients with bleomycn-containing combination chemotherapy was predominantly caused by the bleomycin.
Moreover, a decrease in TLC below the 60% pretreatment value has been used as an argument to reduce or to discontinue the doses of bleomycin nis during treatment (Comis et al., 1979; Ginsberg et al., 1982 Doll et al. (1992) .
Because the decrease in D. is also observed in the BEP group, it can be asumed that bleomycin has only a minor impact on D. and that this decline is also due to effects of etoposide and /or cisplatin. As Van Baneveld et al. (1985) obsered a reduction in D. in patents treated with cisplatin, vinblastin and bleomycin, it is conceivable that cisplatin is the major cause of this decline. The reduction in Vc, which only occurs in patients receiving bleomycin, indicates that bleomycin does have an effect on the lung vasculature, but different from the effect of etoposide and cisplatinL The capillary changes observed usng nailfold capllary microscopic examination (Bellmunt et al., 1987) , the reported cases of Raynaud's phenomenon (Vogelzang et al., 1981; Adoue et al., 1984) , myocardial infarction (Samuels et al., 1987) and pulmonary veno-occlusive disease (Joselson et al., 1983) induced by bleomycin alone or in combination therapy also suggest direct effects of bleomycin on the vasculature. The efects of bleomycin occur predominantly in the hlng and skin vasculature, because these two orgns are, in contrast to other orgns such as the liver, deficient in bleomycin hydrolase which inactivates bleomycin (Ohnuma et al., 1974) .
Bleomycin-related alterations of the vasculature are due to induction of free radials by bleomycin, which causes endothelal damage, followed by an immunological process with infiltration of lymphocytes and alveolar macrophages (Adamson et al., 1974 (Moseley et al., 1986) , production of collagen (Otsuka et al., 1978) and finally fibrosis (Khahl et al., 1989) , which may cause occlusion of capillaries, which probably leads to the observed reduction in Vc in the patients treated with BEP.
Van Barneveld et al. (1985) have shown in patients with testicular cancer a decline in VC during chemotherapy consisting of bleomycin, vinblastine and cisplatin. This study confirms these results, using etoposide instead of vinblastine, and shows that this decline in VC is specifically caused by bleomycin, because this effect only occurs in patients treated with BEP.
The observation that the lung function assessments of the three patients who developed BIP did not differ significantly from the other patients receiving BEP does not confirm the results of Van Barneveld et al. (1985) , although three patients is too small a number to draw conclusions about the usage of the function tests examined for monitoring BIP.
In conclusion, this study shows that the TWcO, widely used to monitor the potential lethal pulmonary toxicity induced by bleomycin as part of a multidrug anti-cancer treatment, is not a proper parameter for this purpose as it actually might measure effects of etoposide and cisplatin. Also, changes in the diffusing capacity of the alveolo-capillary membrane (D.n) and KO are not specific for detecting bleomycin-induced toxicity. In contrast, bleomycin induces pulmonary alterations that are specifically reflected in the pulmonary capillary blood volume (Vc) and vital capacity (VC). These two parameters may be the most suitable for determining bleomycin effects in the lung.
